Home > Market Research Report > Pharmaceutical > Cancer > Global Pipeline Review & Analysis of Hematological Malignancies

Questions?

Bone Disease Treatment (46)

Cancer (883)

Diabetes (159)

Drug Delivery System (184)

Drug Discovery (1403)

Generic Drugs (128)

Infectious Disease (406)

Mental Disease (98)

Neurodegenerative Disease (180)

Obesity Treatment (49)

OTC Drug (149)

Pharmaceutical Companies (561)

Prescription Drugs (120)

Regulation (122)

Vaccines (178)

Veterinary Medicine (28)

Market Research Report

Global Pipeline Review & Analysis of Hematological Malignancies

Published by	BioSeeker Group AB
Published	March, 2007	Product code	50858
Content info	195 pages
Price	US $ 3553 PDF by E-mail (Single User License)

Introduction
Related Reports

Global Pipeline Review & Analysis of Hematological Malignancies published by BioSeeker Group AB in March, 2007. This report consists of 195 pages and the price starts from US $ 3553.

Introduction

Abstract

Introduction

The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.

About this report

In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, BioSeeker reports on the hematological cancer pipeline by:

Investigator - Includes 212 investigators and partners
Drug - Includes 237 “active” drugs
Sub-indication - Includes 11 sub-indications
Developmental stage - Includes 8 developmental stages
Compound type - Includes 21 different compounds types
Targeted therapy strategy - Includes 5 different targeted therapy strategies
Target - Includes 97 different protein targets
Signaling pathway - Includes 18 different signaling pathways

All of above “factors” are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each “factor” included in this cutting edge analysis.

1 EXECUTIVE SUMMARY

2 CANCER HIGHLIGHTS

2.1 LIST OF FIGURES
2.2 LIST OF TABLES

3 PLAYERS IN THE FIELD OF HEMATOLOGICAL MALIGNANCIES

4 THE HEMATOLOGICAL CANCER DRUG PIPELINE

4.1 DRUG PIPELINE BY LEUKEMIA
4.2 DRUG PIPELINE BY LYMPHOMA

5 PROTEIN TARGETS IN HEMATOLOGICAL CANCERS

5.1 PURSUED TARGETS IN LEUKEMIA
5.2 PURSUED TARGETS IN LYMPHOMA

6 COMPOUNDS

6.1 OVERVIEW OF COMPOUNDS
6.2 PRESENTATION OF BIOLOGICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.3 PRESENTATION OF CHEMICAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.4 PRESENTATION OF NATURAL COMPOUNDS USED IN HEMATOLOGICAL CANCERS
6.5 LEUKEMIA BY COMPOUND TYPES
6.6 LYMPHOMA BY COMPOUND TYPE

7 TARGETED THERAPIES IN HEMATOLOGICAL CANCERS

7.1 TARGETED THERAPIES IN LEUKEMIA
7.2 TARGETED THERPIES IN LYMPHOMA

8 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN HEMATOLOGICAL CANCERS

8.1 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LEUKEMIA
8.2 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN LYMPHOMA

9 PURSUED SIGNALING PATHWAYS IN HEMATOLOGICAL CANCERS

9.1 ALPHA6 BETA4 INTEGRIN SIGNALING PATHWAY
- 9.1.1 DESCRIPTION OF PATHWAY
- 9.1.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.2 ANDROGEN RECEPTOR SIGNALING PATHWAY
- 9.2.1 DESCRIPTION OF PATHWAY
- 9.2.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.3 B CELL RECEPTOR SIGNALING PATHWAY
- 9.3.1 DESCRIPTION OF PATHWAY
- 9.3.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.4 EGFR1 SIGNALING PATHWAY
- 9.4.1 DESCRIPTION OF PATHWAY
- 9.4.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.5 ID SIGNALING PATHWAY
- 9.5.1 DESCRIPTION OF PATHWAY
- 9.5.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.6 IL-1 SIGNALING PATHWAY
- 9.6.1 DESCRIPTION OF PATHWAY
- 9.6.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.7 IL-2 SIGNALING PATHWAY
- 9.7.1 DESCRIPTION OF PATHWAY
- 9.7.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.8 IL-3 SIGNALING PATHWAY
- 9.8.1 DESCRIPTION OF PATHWAY
- 9.8.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.9 IL-4 SIGNALING PATHWAY
- 9.9.1 DESCRIPTION OF PATHWAY
- 9.9.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.10 IL-5 SIGNALING PATHWAY
- 9.10.1 DESCRIPTION OF PATHWAY
- 9.10.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.11 IL-6 SIGNALING PATHWAY
- 9.11.1 DESCRIPTION OF PATHWAY
- 9.11.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.12 IL-7 SIGNALING PATHWAY
- 9.12.1 DESCRIPTION OF PATHWAY
- 9.12.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.13 KIT RECEPTOR SIGNALING PATHWAY
- 9.13.1 DESCRIPTION OF PATHWAY
- 9.13.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.14 NOTCH SIGNALING PATHWAY
- 9.14.1 DESCRIPTION OF PATHWAY
- 9.14.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.15 T CELL RECEPTOR SIGNALING PATHWAY
- 9.15.1 DESCRIPTION OF PATHWAY
- 9.15.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.16 TGF-BETA RECEPTOR SIGNALING PATHWAY
- 9.16.1 DESCRIPTION OF PATHWAY
- 9.16.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.17 TNF-ALPHA SIGNALING PATHWAY
- 9.17.1 DESCRIPTION OF PATHWAY
- 9.17.2 HEMATOLOGICAL CANCER DRUG CANDIDATES
9.18 WNT SIGNALING PATHWAY
- 9.18.1 DESCRIPTION OF PATHWAY
- 9.18.2 HEMATOLOGICAL CANCER DRUG CANDIDATES

10 BRIEF DRUG DESCRIPTION

11 DISCLAIMER

11.1 LIABILITY
11.2 COMPLETENESS

List of Figures

Figure 1: The Hematological Cancer Developmental Pipeline
Figure 2: The Leukemia Developmental Pipeline
Figure 3: The Lymphoma Developmental Pipeline
Figure 4: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
Figure 5: Leukemia Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
Figure 6: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Molecular Class of Target
Figure 7: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Primary Target Localization
Figure 8: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Biological Process of Target
Figure 9: Lymphoma Drug Candidates by Developmental Stage, Sub-indication Vrs Molecular Class of Target
Figure 10: Distribution of Compound Types in the Hematological Malignancies Pipeline
Figure 11: Leukemia Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
Figure 12: Lymphoma Drug Candidates Presented by Developmental Stage and Sub-Indication Vrs Compound Type
Figure 13: Leukemia Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
Figure 14: Lymphoma Drug Candidates by Developmental Stage and Sub-indication Vrs Targeted Therapy Type
Figure 15: Angiogenesis - Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 16: Apoptosis - Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 17: Protein Kinase Inhibitors - Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 18: Vaccines - Developmental Stages of Sub indications of Leukemia Versus Compound Type
Figure 19: Angiogenesis - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 20: Apoptosis - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 21: Protein Kinase Inhibitor - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 22: Vaccines - Developmental Stages of Sub indications of Lymphoma Versus Compound Type
Figure 23: Drug Candidates Involving the Alpha6 Beta4 Integrin Signaling Pathway for the Treatment of Hematological Cancers
Figure 24: Drug Candidates Involving the Androgen Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 25: Drug Candidates Involving the B Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 26: Drug Candidates Involving the EGFR1 Signaling Pathway for the Treatment of Hematological Cancers
Figure 27: Drug Candidates Involving the ID Signaling Pathway for the Treatment of Hematological Cancers
Figure 28: Drug Candidates Involving the IL-1 Signaling Pathway for the Treatment of Hematological Cancers
Figure 29: Drug Candidates Involving the IL-2 Signaling Pathway for the Treatment of Hematological Cancers
Figure 30: Drug Candidates Involving the IL-3 Signaling Pathway for the Treatment of Hematological Cancers
Figure 31: Drug Candidates Involving the IL-4 Signaling Pathway for the Treatment of Hematological Cancers
Figure 32: Drug Candidates Involving the IL-5 Signaling Pathway for the Treatment of Hematological Cancers
Figure 33: Drug Candidates Involving the IL-6 Signaling Pathway for the Treatment of Hematological Cancers
Figure 34 Drug Candidates Involving the IL-7 Signaling Pathway for the Treatment of Hematological Cancers
Figure 35: Drug Candidates Involving the Kit Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 36: Drug Candidates Involving the Notch Signaling Pathway for the Treatment of Hematological Cancers
Figure 37: Drug Candidates Involving the T Cell Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 38: Drug Candidates Involving the TGF-beta Receptor Signaling Pathway for the Treatment of Hematological Cancers
Figure 39: Drug Candidates Involving the TNF-alpha Signaling Pathway for the Treatment of Hematological Cancers
Figure 40: Drug Candidates Involving the Wnt Signaling Pathway for the Treatment of Hematological Cancers

List of Tables

Table 1: List of Active Players in the Field of Hematological Malignancies
Table 2: The Leukemia Developmental Pipeline
Table 3: The Lymphoma Developmental Pipeline
Table 4: List of Pursued Protein Targets in Hematological Cancers
Table 5: Hematological Cancer Targets by Investigator and Drug
Table 6: Pursued Targets by Sub-indications of Leukemia
Table 7: Pursued Targets by Sub-indications of Lymphoma
Table 8: Drug Candidates with Its Corresponding Compound Types Listed by Investigator
Table 9: List of Biological Compounds
Table 10: List of Chemical Compounds
Table 11: List of Natural Compounds
Table 12: Developmental Stage and Sub Indication by Compounds Type in Leukemia
Table 13: Developmental Stage and Sub indication bt Compound Types in Lymphoma
Table 14: List of Targeted Therapies in Leukemia
Table 15: List of Targeted Therapies in Lymphoma
Table 16: Targeted Therapy Strategies Versus Compound Type in Leukemia
Table 17: Targeted Therapy Strategies Versus Compound Types in Lymphoma
Table 18: Targets Linking Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
Table 19: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
Table 20: Targets Linking Drugs to the Androgen Receptor Signaling Pathway
Table 21: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Androgen Receptor Signaling Pathway
Table 22: Targets Linking Drugs to the B Cell Receptor Signaling Pathway
Table 23: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the B Cell Receptor Signaling Pathway
Table 24: Targets Linking Drugs to the EGFR1 Signaling Pathway
Table 25: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the EGFR1 Signaling Pathway
Table 26: Targets Linking Drugs to the ID Signaling Pathway
Table 27: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the ID Signaling Pathway
Table 28: Targets Linking Drugs to the IL-1 Signaling Pathway
Table 29: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-1 Signaling Pathway
Table 30: Targets Linking Drugs to the IL-2 Signaling Pathway
Table 31: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-2 Signaling Pathway
Table 32: Targets Linking Drugs to the IL-3 Signaling Pathway
Table 33: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-3 Signaling Pathway
Table 34: Targets Linking Drugs to the IL-4 Signaling Pathway
Table 35: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-4 Signaling Pathway
Table 36: Targets Linking Drugs to the IL-5 Signaling Pathway
Table 37: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-5 Signaling Pathway
Table 38: Targets Linking Drugs to the IL-6 Signaling Pathway
Table 39: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-6 Signaling Pathway
Table 40: Targets Linking Drugs to the IL-7 Signaling Pathway
Table 41: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the IL-7 Signaling Pathway
Table 42: Targets Linking Drugs to the Kit Receptor Signaling Pathway
Table 43: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Kit Receptor Signaling Pathway
Table 44: Targets Linking Drugs to theNotch Signaling Pathway
Table 45: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Notch Signaling Pathway
Table 46: Targets Linking Drugs to the T Cell Receptor Signaling Pathway
Table 47: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the T Cell Receptor Signaling Pathway
Table 48: Targets Linking Drugs to the TGF-beta Signaling Pathway
Table 49: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TGF-beta Receptor Signaling Pathway
Table 50: Targets Linking Drugs to the TNF-alpha Signaling Pathway
Table 51: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the TNF-alpha Signaling Pathway
Table 52: Targets Linking Drugs to the Wnt Signaling Pathway
Table 53: Drugs, Listed by Sub Indication and Developmental Stage, Targeting the Wnt Signaling Pathway

Introduction
Related Reports

User Guide About Us Policies Site Map

Int'l: +1-860-674-8796 US: +1-866-353-3335 (Toll Free) | EU: +32-2-535-7543

Global Pipeline Review & Analysis of Hematological Malignancies

Introduction

Abstract

Introduction

About this report

Table of Contents

1 EXECUTIVE SUMMARY

2 CANCER HIGHLIGHTS

TABLE OF CONTENTS

3 PLAYERS IN THE FIELD OF HEMATOLOGICAL MALIGNANCIES

4 THE HEMATOLOGICAL CANCER DRUG PIPELINE

5 PROTEIN TARGETS IN HEMATOLOGICAL CANCERS

6 COMPOUNDS

7 TARGETED THERAPIES IN HEMATOLOGICAL CANCERS

8 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN HEMATOLOGICAL CANCERS

9 PURSUED SIGNALING PATHWAYS IN HEMATOLOGICAL CANCERS

10 BRIEF DRUG DESCRIPTION

11 DISCLAIMER

List of Figures

List of Tables

Global Pipeline Review & Analysis of Hematological Malignancies

Introduction

Abstract

Introduction

About this report

Table of Contents

1 EXECUTIVE SUMMARY

2 CANCER HIGHLIGHTS

TABLE OF CONTENTS

3 PLAYERS IN THE FIELD OF HEMATOLOGICAL MALIGNANCIES

4 THE HEMATOLOGICAL CANCER DRUG PIPELINE

5 PROTEIN TARGETS IN HEMATOLOGICAL CANCERS

6 COMPOUNDS

7 TARGETED THERAPIES IN HEMATOLOGICAL CANCERS

8 TARGETED THERAPY STRATEGIES VERSUS COMPOUND TYPES IN HEMATOLOGICAL CANCERS

9 PURSUED SIGNALING PATHWAYS IN HEMATOLOGICAL CANCERS

10 BRIEF DRUG DESCRIPTION

11 DISCLAIMER

List of Figures

List of Tables

Related Reports

Cancer Report

Pharmaceutical Market Report by BioSeeker Group AB